Celgene’s long-term growth factors
Celgene (CELG) has a focused and robust clinical pipeline that may help it launch new drugs in the future. The company’s key areas of focus for drug development include multiple myeloma, myelodysplastic syndromes (or MDS), acute myeloid leukemia (or AML), lymphoma, acute lymphocytic leukemia (or ALL), chronic lymphocytic leukemia (or CLL), beta-thalassemia, solid tumors, immunology and inflammation, and cellular therapies.
The company expects that by 2018, nine of its investigational drugs may advance to pivotal registration trials. Currently, Celgene is involved in more than 180 ongoing clinical trials. The company expects to release data from more than 19 phase three trials by the end of 2018.
Revilmid’s method of use patent in the US will expire in 2027, and its European method of use patent will expire in 2024. Abraxane will lose its method of use patent exclusivity in the US only after 2026. In Europe, Abraxane’s use/formulation patent will expire in 2022. Pomalyst and Otezla patents on drug substance will face US patent expiry in 2024.
If Celgene sees continued revenue growth, it could boost the share prices of the iShares Nasdaq Biotechnology ETF (IBB). Celgene accounts for ~7.9% of IBB’s total portfolio holdings.
Out of 28 analysts analyzing Celgene in June 2017, 11 analysts recommended a “strong buy,” while another 11 recommended a “buy.” Five analysts recommended a “hold,” while one analyst recommended a “sell.” Around 79% of analysts covering Celgene suggested some form of buy.
Of the 13 analysts analyzing Bluebird Bio (BLUE) in June 2017, five analysts recommended a “strong buy,” while six analysts recommended a “buy.” One analyst suggested a “hold,” and one analyst recommended a “sell.” Around 85% of analysts covering Bluebird Bio suggested some form of buy.
In June 2017, 25 analysts were analyzing Regeneron Pharmaceuticals (REGN). Of 25 analysts, eight analysts suggested a “strong buy,” while five analysts suggested a “buy.” Twelve analysts recommended a “hold,” while none of the analysts recommended a “sell” or “strong sell.” Around 52% of the analysts recommended some form of buy.
Out of 25 analysts analyzing Vertex Pharmaceuticals (VRTX) in June, eight analysts recommended a “strong buy” while another eight analysts recommended a “buy.” Nine analysts recommended a “hold,” but none suggested a “sell” or “strong sell.”